Aggressive antipyretics in central nervous system malaria: Study protocol of a randomized-controlled trial assessing antipyretic efficacy and parasite clearance effects (Malaria FEVER study).
Moses B ChilombeMichael P McDermottKarl B SeydelManoj MathewsMusaku MwenechanyaGretchen L BirbeckPublished in: PloS one (2022)
This clinical trial seeks to challenge the practice paradigm of limited fever treatment based upon hyperpyrexia by evaluating the fever-reduction efficacy of more aggressive antipyretic using two antipyretics and prophylactic administration and will elucidate the impact of antipyretics on parasite clearance and acute symptomatic seizures. If aggressive antipyretic therapy is shown to safely reduce the maximum temperature, a clinical trial evaluating the neuroprotective effects of temperature reduction in CNS malaria is warranted.
Keyphrases
- plasmodium falciparum
- clinical trial
- study protocol
- open label
- phase ii
- double blind
- randomized controlled trial
- primary care
- healthcare
- liver failure
- respiratory failure
- phase iii
- blood brain barrier
- cerebral ischemia
- cerebrospinal fluid
- drug induced
- quality improvement
- bone marrow
- stem cells
- aortic dissection
- mesenchymal stem cells
- extracorporeal membrane oxygenation
- replacement therapy